Document Detail


Cancer and venous thromboembolism: prevention, treatment and survival.
MedLine Citation:
PMID:  17906917     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Venous thromboembolism (VTE) occurs frequently in patients with cancer. It can be difficult to manage, sometimes delay cancer therapy and predicts for a worse prognosis. Hence, effective methods to prevent and treat VTE can reduce morbidity and mortality. Prophylaxis with anticoagulants is recommended for patients hospitalized for surgery or medical conditions, but is not routinely administered in the ambulatory setting. Traditional anticoagulation with a heparin followed by vitamin K antagonist therapy for cancer patients with acute VTE is associated with a high frequency of treatment failure and bleeding complications. Low molecular weight heparins (LMWHs) have simplified and improved the management of VTE, and recent studies suggest these agents may improve survival in patients with limited or early stage disease. This brief review will provide an update on the primary prevention and treatment of VTE and discuss the evidence for the survival advantage associated with LMWH use in patients with malignancy.
Authors:
Agnes Yuet Ying Lee
Related Documents :
10912637 - Cancer, thrombosis, and anticoagulants.
15256057 - Regulation of gene expression and inhibition of experimental prostate cancer bone metas...
17855717 - Litigating the science of breast cancer treatment.
21850037 - What does physics have to do with cancer?
25378147 - Vitamin d and skin cancer;
12851837 - The place of lymphatic mapping and sentinel node biopsy in oncology.
Publication Detail:
Type:  Journal Article; Review     Date:  2007-09-29
Journal Detail:
Title:  Journal of thrombosis and thrombolysis     Volume:  25     ISSN:  0929-5305     ISO Abbreviation:  J. Thromb. Thrombolysis     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-01-07     Completed Date:  2008-03-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502018     Medline TA:  J Thromb Thrombolysis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  33-6     Citation Subset:  IM    
Affiliation:
Department of Medicine, McMaster University, Hamilton, ON, Canada. alee@mcmaster.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Neoplasms / complications,  drug therapy*,  mortality
Venous Thromboembolism / drug therapy*,  etiology,  prevention & control
Warfarin / therapeutic use
Chemical
Reg. No./Substance:
0/Heparin, Low-Molecular-Weight; 81-81-2/Warfarin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Determinants and measures of quality in oral anticoagulation therapy.
Next Document:  Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation int...